{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:44:52Z","timestamp":1788291892723,"version":"build-2803163510"},"reference-count":54,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatopathology"],"abstract":"<jats:p>Inflammatory skin diseases are characterized by complex interactions between immune pathways, epidermal barrier function, and environmental triggers, leading to distinct clinical and histopathological features. This narrative review aims to integrate current knowledge on the cutaneous immune microenvironment across major inflammatory skin diseases, including atopic dermatitis, psoriasis, hidradenitis suppurativa, and vitiligo. A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus, focusing on studies published between 2021 and early 2026. The findings highlight disease-specific immune signatures, such as Th2-driven inflammation in atopic dermatitis, IL-23\/Th17 axis activation in psoriasis, neutrophil-dominated responses in hidradenitis suppurativa, and cytotoxic T-cell-mediated melanocyte destruction in vitiligo. These molecular pathways are closely reflected in histopathological patterns, emphasizing the link between morphology and immunopathogenesis. Advances in targeted therapies, including biologics and Janus kinase inhibitors, demonstrate the clinical relevance of these pathways and support a transition toward mechanism-based treatment strategies. Dermatopathology is increasingly contributing to precision medicine approaches by supporting correlations between tissue features, immune pathways, and potential therapeutic targets. This review provides a framework for improved disease stratification and for the development of personalized treatment strategies in inflammatory skin diseases.<\/jats:p>","DOI":"10.3390\/dermatopathology13020022","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:10:42Z","timestamp":1778505042000},"page":"22","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9603-6256","authenticated-orcid":false,"given":"Andreea C\u0103t\u0103lina","family":"Tinca","sequence":"first","affiliation":[{"name":"Pathophysiology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540142 Targu Mures, Romania"},{"name":"Pathology Department, Clinical County Hospital Mure\u0219, 540136 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3296-1661","authenticated-orcid":false,"given":"Andreea Raluca","family":"Cozac-Szoke","sequence":"additional","affiliation":[{"name":"Pathophysiology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu Simion","family":"Cotoi","sequence":"additional","affiliation":[{"name":"Pathophysiology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540142 Targu Mures, Romania"},{"name":"Pathology Department, Clinical County Hospital Mure\u0219, 540136 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Andrzejczak, K., Sternak, A., Witkowski, W., and Ponikowska, M. (2025). Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?. Cells, 14.","DOI":"10.3390\/cells14181442"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/all.15816","article-title":"CLA+ memory T cells in atopic dermatitis","volume":"79","author":"Czarnowicki","year":"2024","journal-title":"Allergy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"153477","DOI":"10.1016\/j.prp.2021.153477","article-title":"STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology","volume":"223","author":"Karpathiou","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s12016-025-09057-y","article-title":"Atopic Dermatitis: The Relationship Between Immune Mediators and Skin Lipid Barrier","volume":"68","author":"You","year":"2025","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.semcdb.2022.01.006","article-title":"Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling","volume":"128","author":"Kashyap","year":"2022","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12016-021-08880-3","article-title":"Update on the Pathogenesis and Therapy of Atopic Dermatitis","volume":"61","author":"Li","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/13543784.2024.2326625","article-title":"Microbiome modulators for atopic eczema: A systematic review of experimental and investigational therapeutics","volume":"33","author":"Greenzaid","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.alit.2025.02.001","article-title":"Neuroimmune mechanisms of type 2 inflammation in the skin and lung","volume":"74","author":"Tamari","year":"2025","journal-title":"Allergol. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.alit.2022.04.003","article-title":"Peripheral itch sensitization in atopic dermatitis","volume":"71","author":"Tominaga","year":"2022","journal-title":"Allergol. Int. Off. J. Jpn. Soc. Allergol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/14656566.2021.1999412","article-title":"The evolving atopic dermatitis management landscape","volume":"23","author":"Sahni","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40257-023-00793-5","article-title":"Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis","volume":"24","author":"Bernardo","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2217\/imt-2023-0066","article-title":"The role of lebrikizumab in the treatment of atopic dermatitis in the adult population","volume":"15","author":"Prajapati","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/10600280221105686","article-title":"Review of Tralokinumab in the Treatment of Atopic Dermatitis","volume":"57","author":"Singh","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2217\/imt-2022-0307","article-title":"The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents","volume":"15","author":"Ewulu","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2147\/CCID.S267217","article-title":"Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data","volume":"15","author":"Kelly","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s13555-025-01477-0","article-title":"JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis)","volume":"15","author":"Rossi","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ko\u0142kowski, K., Trzeciak, M., and Soko\u0142owska-Wojdy\u0142o, M. (2021). Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413388"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40257-024-00913-9","article-title":"Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment","volume":"26","author":"Gorelick","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The Immunology of Psoriasis-Current Concepts in Pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Singh, R., Koppu, S., Perche, P.O., and Feldman, S.R. (2021). The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312793"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"ii64","DOI":"10.1093\/ecco-jcc\/jjab185","article-title":"Blockade of IL-23: What is in the Pipeline?","volume":"16","author":"Parigi","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kamata, M., and Tada, Y. (2023). Crosstalk: Keratinocytes and immune cells in psoriasis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1286344"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-020-00585-1","article-title":"HLA-Cw1 and Psoriasis","volume":"22","author":"Huang","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Vi\u010di\u0107, M., Ka\u0161telan, M., Brajac, I., Soto\u0161ek, V., and Massari, L.P. (2021). Current Concepts of Psoriasis Immunopathogenesis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111574"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/apm.13221","article-title":"Role of IL-22 in homeostasis and diseases of the skin","volume":"130","author":"Lopez","year":"2022","journal-title":"APMIS"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s12276-025-01535-9","article-title":"Th17 cell pathogenicity in autoimmune disease","volume":"57","author":"Park","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lee, H.J., Hong, Y.J., and Kim, M. (2021). Angiogenesis in Chronic Inflammatory Skin Disorders. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222112035"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2147\/JEP.S265632","article-title":"Experimental Pharmacological Management of Psoriasis","volume":"13","author":"Campione","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2119767","DOI":"10.1080\/21645515.2022.2119767","article-title":"Review of bimekizumab in the treatment of psoriasis","volume":"18","author":"Koppu","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: Results from an Italian 28-week retrospective study","volume":"33","author":"Megna","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2436015","DOI":"10.1080\/09546634.2024.2436015","article-title":"Off-label dermatologic uses of IL-23 inhibitors","volume":"35","author":"Porter","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tashiro, T., and Sawada, Y. (2022). Psoriasis and Systemic Inflammatory Disorders. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084457"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tate, A.R., and Rao, G.H.R. (2024). Inflammation: Is It a Healer, Confounder, or a Promoter of Cardiometabolic Risks?. Biomolecules, 14.","DOI":"10.3390\/biom14080948"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40257-025-00949-5","article-title":"Disease Modification in Psoriasis: Future Prospects for Long-Term Remission","volume":"26","author":"Ranzinger","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Cascio Ingurgio, R., Alfano, A., Matteodo, E., Ibba, L., Gargiulo, L., Paolino, G., Mercuri, S.R., Carugno, A., Zerbinati, N., and Bighetti, S. (2026). Tildrakizumab in Managing Psoriasis with Involvement of Difficult-to-Treat Areas: A Multicenter Real-Life Retrospective Study. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020631"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Scala, E., Cacciapuoti, S., Garzorz-Stark, N., Megna, M., Marasca, C., Seiringer, P., Volz, T., Eyerich, K., and Fabbrocini, G. (2021). Hidradenitis Suppurativa: Where We Are and Where We Are Going. Cells, 10.","DOI":"10.3390\/cells10082094"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Spiteri, J., Mintoff, D., Grech, L., and Pace, N.P. (2025). Transcriptomic Signatures and Molecular Pathways in Hidradenitis Suppurativa-A Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167704"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jid.2021.05.036","article-title":"Altered Skin and Gut Microbiome in Hidradenitis Suppurativa","volume":"142","author":"McCarthy","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jid.2024.04.035","article-title":"IRAK4 Is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers","volume":"145","author":"McDonald","year":"2025","journal-title":"J. Investig. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000536268","article-title":"Cytokine-Mediated Molecular Pathophysiology of Hidradenitis Suppurativa: A Narrative Review","volume":"10","author":"Melchor","year":"2024","journal-title":"Skin Appendage Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100350","DOI":"10.1016\/j.xjidi.2025.100350","article-title":"Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity","volume":"5","author":"Vecin","year":"2025","journal-title":"JID Innov."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Markota \u010cagalj, A., Marinovi\u0107, B., and Bukvi\u0107 Mokos, Z. (2022). New and Emerging Targeted Therapies for Hidradenitis Suppurativa. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073753"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Meldrum, E., and Ingram, J.R. (2026). Targeting Neutrophil Function as Therapy for Hidradenitis Suppurativa. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27042076"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/1346-8138.17031","article-title":"New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review","volume":"51","author":"Yamanaka","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2270091","DOI":"10.1080\/09546634.2023.2270091","article-title":"Brodalumab for severe hidradenitis suppurativa: A case of clinico-radiologic improvement and literature review","volume":"34","author":"Vagnozzi","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103841","DOI":"10.1016\/j.autrev.2025.103841","article-title":"Genetic and immune dysregulation in vitiligo: Insights into autoimmune mechanisms and disease pathogenesis","volume":"24","author":"Upadhya","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1002\/ski2.460","article-title":"Vitiligo: From mechanisms of disease to treatable pathways","volume":"4","author":"Pathak","year":"2024","journal-title":"Skin Health Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/1346-8138.70067","article-title":"Pathogenesis of Vitiligo: Integrating Immune and Non-Immune Cell Crosstalk","volume":"53","author":"Inoue","year":"2026","journal-title":"J. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/cei\/uxab002","article-title":"Patho-immunological mechanisms of vitiligo: The role of the innate and adaptive immunities and environmental stress factors","volume":"207","author":"Faraj","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Qi, F., Liu, F., and Gao, L. (2021). Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.790125"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.5826\/dpc.1501a4600","article-title":"Treatment Advances in Vitiligo: An Updated Review","volume":"15","author":"Ismail","year":"2025","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bettolini, L., Maione, V., Carugno, A., Fratton, Z., Errichetti, E., Crivellari, M., Cartocci, A., Maronese, C.A., Venturini, M., and Zerbinati, N. (2026). Predictors of Response to Topical Ruxolitinib in Non-segmental Vitiligo: A Narrative Review. Australas. J. Dermatol., Online ahead of print.","DOI":"10.1111\/ajd.70090"}],"container-title":["Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2296-3529\/13\/2\/22\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T14:01:36Z","timestamp":1778508096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2296-3529\/13\/2\/22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["dermatopathology13020022"],"URL":"https:\/\/doi.org\/10.3390\/dermatopathology13020022","relation":{},"ISSN":["2296-3529"],"issn-type":[{"value":"2296-3529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]}}}